Want to see HK:1466 full AI Analyst Report?
1466 Stock Chart & Stats
HK$1.00
-HK$0.03(-3.00%)
At close: 4:00 PM EDT
HK$1.00
-HK$0.03(-3.00%)
Day’s Range― - ―
52-Week RangeHK$0.47 - HK$1.70
Previous CloseN/A
Volume490.00K
Average Volume (3M)304.34K
Market Cap
HK$1.01B
Enterprise ValueHK$487.53
Total Cash (Recent Filing)HK$43.11M
Total Debt (Recent Filing)HK$28.41M
Price to Earnings (P/E)―
Beta-0.53
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding932,254,100
10 Day Avg. Volume457,992
30 Day Avg. Volume304,341
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.69
Price to Sales (P/S)5.57
P/FCF Ratio-22.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved LeverageA materially lower debt-to-equity ratio (~0.15) meaningfully reduces refinancing and interest risk, extending the firm's financial runway. This stronger capital structure provides durable resilience to sustain operations while management repairs profitability or executes restructuring.
Sizable Equity BufferA relatively large equity base versus assets gives the company a durable loss-absorption buffer. That structural capital strength protects creditors, supports liquidity access, and preserves capacity for strategic actions (R&D, partnerships, or selective M&A) without immediate solvency risk.
Industry Structural TailwindsOperating in specialty and generic pharmaceuticals offers long-term demand durability and high barriers to entry from regulation and approvals. If the company stabilizes operations, the industry structure supports recurring revenue potential and opportunities to leverage product development capabilities.
Bears Say
Negative Operating Cash FlowPersistently negative operating cash flow indicates the core business is not self-funding. Over the medium term this creates structural funding risk, increasing reliance on external financing, dilutive capital raises, or asset sales, which can constrain investment in growth or product pipelines.
Sharp Revenue DeclineA steep multi-year revenue decline reflects weakening demand, lost customers, or competitive pressures. Sustainably reversing such a drop is difficult; persistent top-line erosion reduces scale, impairs margins, and lowers returns on R&D and commercial investments over the coming quarters.
Deep Negative ProfitabilityVery low gross margin and ~-42% net margin signal structural profitability issues and poor operating leverage. Such entrenched losses erode shareholder value, consume capital, and make it harder to rebuild margins without substantive business model change or cost restructuring.
Affluent Partners Holdings News
1466 FAQ
What was Affluent Partners Holdings Ltd’s price range in the past 12 months?
Affluent Partners Holdings Ltd lowest stock price was HK$0.47 and its highest was HK$1.70 in the past 12 months.
What is Affluent Partners Holdings Ltd’s market cap?
Affluent Partners Holdings Ltd’s market cap is HK$1.01B.
When is Affluent Partners Holdings Ltd’s upcoming earnings report date?
Affluent Partners Holdings Ltd’s upcoming earnings report date is Nov 26, 2026 which is in 100 days.
How were Affluent Partners Holdings Ltd’s earnings last quarter?
Affluent Partners Holdings Ltd released its earnings results on Jun 30, 2026. The company reported -HK$0.048 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Affluent Partners Holdings Ltd overvalued?
According to Wall Street analysts Affluent Partners Holdings Ltd’s price is currently Overvalued.
Does Affluent Partners Holdings Ltd pay dividends?
Affluent Partners Holdings Ltd does not currently pay dividends.
What is Affluent Partners Holdings Ltd’s EPS estimate?
Affluent Partners Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Affluent Partners Holdings Ltd have?
Affluent Partners Holdings Ltd has 932,254,100 shares outstanding.
What happened to Affluent Partners Holdings Ltd’s price movement after its last earnings report?
Affluent Partners Holdings Ltd reported an EPS of -HK$0.048 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -19.231%.
Which hedge fund is a major shareholder of Affluent Partners Holdings Ltd?
Currently, no hedge funds are holding shares in HK:1466
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Affluent Partners Holdings Ltd
Affluent Partners Holdings Limited, an investment holding entity founded in 2014 and situated in Central, Hong Kong, conducts various operations. Its core business involves the full lifecycle of pearls and jewelry products, including their acquisition, processing, design, manufacturing, assembly, trading, and wholesale distribution. The company's activities are structured into two distinct divisions: the sale of pearl and jewelry items, and strategic investment alongside financial services. Additionally, it allocates capital to financial assets within the real estate sector. Affluent Partners operates internationally, with a footprint in Hong Kong, the United Kingdom, the United States, Japan, Europe, and mainland China. This enterprise was previously known as Man Sang Jewellery Holdings Limited, undergoing a name change to Affluent Partners Holdings Limited in February 2017.
Technical Analysis
Citychamp Watch & Jewellery Group
―
Emperor Watch & Jewellery
―
Hengdeli Holdings
―
Oriental Watch Holdings
―
Ernest Borel Holdings Ltd
―